Therapeutic potential of the chemokine-receptor duo fractalkine/CX3CR1: an update

D'Haese J. G., Friess H., Ceyhan G.

EXPERT OPINION ON THERAPEUTIC TARGETS, cilt.16, sa.6, ss.613-618, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 16 Sayı: 6
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1517/14728222.2012.682574
  • Dergi Adı: EXPERT OPINION ON THERAPEUTIC TARGETS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.613-618
  • Anahtar Kelimeler: cancer, CX3CL1, CX3CR1, fractalkine, inflammation, neuropathic pain, therapeutic target, FOCAL CEREBRAL-ISCHEMIA, MICROGLIAL ACTIVATION, NEUROPATHIC PAIN, SPINAL-CORD, MOUSE MODEL, CX3CR1, CX(3)CR1, INFLAMMATION, FIBROSIS, CELLS
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Introduction: The chemokine fractalkine/CX3CL1 and its highly selective receptor CX3CR1 mediate critical physiological events during inflammatory responses. The fractalkine/CX3CR1 axis has been shown to play a key role in the pathogenesis and the progression of a large number of diseases in which imbalance of the immune response is frequently seen. Since our last review published in early 2010, the fractalkine/CX3CR1 axis has gained vast attention as a potential therapeutic target in the scientific community, which can be clearly seen in the large number of studies that have been published on this issue since then.